See more : Gold Fields Limited (GFIOF) Income Statement Analysis – Financial Results
Complete financial analysis of Catalyst Pharmaceuticals, Inc. (CPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalyst Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hankuk Carbon Co., Ltd. (017960.KS) Income Statement Analysis – Financial Results
- Al Khaleej Training and Education Company (4290.SR) Income Statement Analysis – Financial Results
- Recruiter.com Group, Inc. (RCRT) Income Statement Analysis – Financial Results
- Ind Bank Housing Limited (INDBNK.BO) Income Statement Analysis – Financial Results
- Brookfield Property REIT Inc. (BPYU) Income Statement Analysis – Financial Results
Catalyst Pharmaceuticals, Inc. (CPRX)
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 84.53M | 34.39M | 21.88M | 17.04M | 14.76M | 19.92M | 45.69K | 43.41K | 34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 313.67M | 179.81M | 118.95M | 102.03M | 87.55M | -19.42M | -45.69K | -43.41K | -34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.77% | 83.94% | 84.46% | 85.69% | 85.57% | -3,883.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.15M | 19.79M | 16.94M | 16.50M | 18.84M | 19.92M | 11.38M | 11.37M | 11.80M | 10.12M | 8.10M | 2.66M | 3.38M | 2.31M | 5.10M | 8.71M | 2.99M | 989.14K | 1.46M | 378.25K | 0.00 | 137.68K |
| General & Administrative | 47.02M | 28.71M | 23.48M | 20.67M | 33.58M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 86.69M | 29.47M | 26.15M | 23.57M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.71M | 58.18M | 49.63M | 44.23M | 36.88M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 2.04M | 1.91M | 359.28K | 164.70K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -428.62K | 118.27K |
| Operating Expenses | 259.43M | 77.97M | 66.56M | 60.73M | 55.72M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Cost & Expenses | 311.39M | 112.37M | 88.45M | 77.77M | 70.48M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Interest Income | 0.00 | 0.00 | 282.00K | 587.00K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.88M | 1.49M | 484.00K | 885.32K | 297.73K | 37.98K | 45.69K | 43.41K | 34.47K | 26.57K | 22.48K | 10.89K | 42.84K | 25.74K | 30.23K | 32.76K | 15.76K | 4.93K | 1.37K | 366.00 | 0.00 | 0.00 |
| EBITDA | 119.69M | 101.84M | 52.39M | 41.30M | 31.82M | -35.26M | -18.49M | -18.03M | -20.46M | -13.57M | -8.40M | -6.35M | -6.35M | -4.00M | -7.21M | -10.53M | -5.01M | -2.72M | -1.82M | -542.59K | -428.62K | -255.95K |
| EBITDA Ratio | 30.06% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -817.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 86.81M | 101.84M | 52.39M | 41.30M | 31.82M | -35.30M | -18.68M | -19.28M | -20.40M | -14.59M | -10.31M | -5.22M | -6.08M | -4.02M | -7.28M | -10.89M | -5.03M | -2.90M | -1.82M | -542.96K | -428.62K | -255.95K |
| Operating Income Ratio | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -823.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.70M | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 267.26K | 1.21M | 165.39K | -917.63K | -1.84M | 1.14M | -308.92K | 17.86K | 33.47K | 329.35K | 887.64K | 172.87K | 16.79K | 3.14K | 0.00 | 0.00 |
| Income Before Tax | 94.51M | 104.72M | 52.67M | 41.89M | 33.41M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | 0.00 | -255.95K |
| Income Before Tax Ratio | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.10M | 21.64M | 13.19M | -33.09M | 1.53M | 2.58M | 141.22K | -929.54K | -99.47K | 993.87K | 1.84M | -1.16M | 308.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.62K | 0.00 |
| Net Income | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | -428.62K | -255.95K |
| Net Income Ratio | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| EPS Diluted | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| Weighted Avg Shares Out | 106.28M | 103.37M | 103.38M | 103.51M | 102.94M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
| Weighted Avg Shares Out (Dil) | 113.75M | 111.38M | 107.80M | 106.24M | 106.02M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.24 per share a year ago.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase
CPRX vs. STVN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return
Pick these four top-ranked stocks, VRT, LMB, ATAT and CPRX, with solid net profit margins to enhance your portfolio returns.
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET
CPRX or STVN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
What Makes Catalyst (CPRX) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Unlock Your Portfolio Value With These 4 High Earnings Yield Stocks
Add value to your portfolio with high earnings yield stocks like GOLD, CPRX, ALGT and AMX amid market uncertainty.
Source: https://incomestatements.info
Category: Stock Reports